Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Significant Drop in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 6,000 shares, a decrease of 80.0% from the February 28th total of 30,000 shares. Based on an average daily volume of 82,900 shares, the days-to-cover ratio is presently 0.1 days. Currently, 1.1% of the company’s stock are sold short.

Bluejay Diagnostics Price Performance

Bluejay Diagnostics stock opened at $3.84 on Friday. The firm’s fifty day moving average price is $3.83 and its 200 day moving average price is $4.58. The company has a market capitalization of $2.12 million, a price-to-earnings ratio of 0.00 and a beta of 0.38. Bluejay Diagnostics has a 12-month low of $3.03 and a 12-month high of $323.92.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Bluejay Diagnostics stock. Anson Funds Management LP grew its holdings in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) by 359.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 319,280 shares of the company’s stock after buying an additional 249,770 shares during the quarter. Anson Funds Management LP owned 1.93% of Bluejay Diagnostics worth $41,000 as of its most recent SEC filing. 18.47% of the stock is owned by institutional investors and hedge funds.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.